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Abstract
Background: Chemotherapy resistance remains a major obstacle in the treatment of women with
ovarian cancer. Establishing predictive markers of chemoresponse would help to individualize
therapy and improve survival of ovarian cancer patients. Chemotherapy resistance in ovarian
cancer has been studied thoroughly and several non-overlapping single genes, gene profiles and
copy number alterations have been suggested as potential markers. The objective of this study was
to explore genetic alterations behind chemotherapy resistance in ovarian cancer with the ultimate
aim to find potential predictive markers.
Methods: To create the best opportunities for identifying genetic alterations of importance for
resistance, we selected a homogenous tumor material concerning histology, stage and
chemotherapy. Using high-resolution whole genome array comparative genomic hybridization
(CGH), we analyzed the tumor genomes of 40 fresh-frozen stage III ovarian serous carcinomas, all
uniformly treated with combination therapy paclitaxel/carboplatin. Fisher's exact test was used to
identify significant differences. Subsequently, we examined four genes in the significant regions
(EVI1, MDS1, SH3GL2, SH3KBP1) plus the ABCB1 gene with quantitative real-time polymerase chain
reaction (QPCR) to evaluate the impact of DNA alterations on the transcriptional level.
Results: We identified gain in 3q26.2, and losses in 6q11.2-12, 9p22.3, 9p22.2-22.1, 9p22.1-21.3,
Xp22.2-22.12, Xp22.11-11.3, and Xp11.23-11.1 to be significantly associated with chemotherapy
resistance. In the gene expression analysis, EVI1 expression differed between samples with gain
versus without gain, exhibiting higher expression in the gain group.
Conclusion: In conclusion, we detected specific genetic alterations associated with resistance, of
which some might be potential predictive markers of chemotherapy resistance in advanced ovarian
serous carcinomas. Thus, further studies are required to validate these findings in an independent
ovarian tumor series.
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Background
In advanced epithelial ovarian cancer, current standard
first-line chemotherapy is platinum- and taxane-based;
most frequently in the form of carboplatin and paclitaxel.
Most patients initially respond to this chemotherapy (60-
80%), but the majority eventually recurs with chemore-
sistant tumor and succumbs to metastatic disease [1,2].
Thus, ovarian cancer is the most lethal gynecologic malig-
nancy with a five-year survival of around 30% in advanced
stage disease; about 70-80% of patients are diagnosed
with advanced stages [3]. Finding predictive markers of
chemoresistance and elucidating resistance mechanisms
is hence crucial for individualizing and improving treat-
ment and survival of ovarian cancer patients. Drug resist-
ance in ovarian cancer is extensively studied and has
proved to be complex, occurring at different cellular levels
as well as on a pharmacological level. The frequently used
chemotherapy paclitaxel exerts its cytotoxic effect by bind-
ing to -tubulin, thereby stabilizing the microtubules and
inducing apoptosis [4]. Multiple resistance mechanisms
have been suggested for paclitaxel; such as alterations of
tubulin/microtubules, altered signaling pathways of the
cell cycle and apoptosis, and over expression of multidrug
efflux pumps [5,6]. The platinum agent carboplatin
induces apoptosis by forming platinum-DNA adducts [7].
Carboplatin resistance mechanisms include decreased net
intracellular drug accumulation, drug detoxification,
enhanced DNA repair mechanisms, or changes in apop-
totic signaling pathways [8-11].
Genetic changes such as copy number alterations (CNAs)
are important in tumor development, and therefore most
likely of importance for chemotherapy resistance as well.
A useful key technique to study CNAs with is the array for-
mat of comparative genomic hybridization (CGH), a
high-resolution genome-wide screening method that
detects and maps copy number changes in the tumor
genome. There are a few reports utilizing array CGH when
studying chemotherapy resistance in ovarian cancer [12-
15], and in addition there are a number of reports per-
formed with conventional metaphase CGH [16-19].
Unfortunately, the overall concurrence is low, pin-point-
ing the need of further studies.
Even though taxane- and platinum resistance has been
greatly studied there is still much to elucidate. In the
present investigation, we sought to identify genetic altera-
tions of importance for chemotherapy resistance in
advanced ovarian cancer, with the ultimate aim to
uncover predictive markers. We selected a homogenous
primary tumor material concerning histology, stage and
chemotherapy response to create the best opportunities
for identifying genetic alterations of importance for resist-
ance. High-resolution whole genome array CGH was used
to scan tumor genomes of fresh-frozen stage III ovarian
serous carcinomas. Subsequently, we examined five genes
(EVI1,  MDS1,  SH3GL2,  SH3KBP1, and ABCB1) with
quantitative real-time polymerase chain reaction (QPCR)
to explore the impact of DNA alterations on the transcrip-
tional level.
Methods
Tumor material
Forty stage III epithelial ovarian serous papillary carcino-
mas were analyzed with array CGH (Table 1; Additional
file 1:Clinical characteristics). The tumors were collected
at the time for primary debulking surgery and stored in -
80°C until analysis. All patients were, following surgery,
uniformly treated with combination chemotherapy pacli-
taxel/carboplatin. Patients were defined as clinically
resistant when they had steady disease or progressive dis-
ease after first-line chemotherapy, or recurrent disease
within six months after the last administration of first-line
chemotherapy. Twenty patients were resistant according
to these criteria. Patients were defined as clinically sensi-
tive when they had clinical complete remission after first-
line chemotherapy (20 patients). All 20 sensitive cases
survived more than five years from diagnosis, and all
resistant cases were primary resistant.
The tumors were classified histologically using standard
World Health Organization (WHO) criteria, and clinical
Table 1: Clinicopathologic characteristics
No. r/s
Chemotherapy response
Resistant 20
Sensitive 20
Survival
Deceased 20
Survivors 20
Histology
Serous 40
FIGO stage
Stage III 40
FIGO grade
Well 8 2/6
Moderately 11 8/3
Poorly 21 10/11
Tumors used in QPCR 17 8/9
Total 40
Clinicopahtologic characteristics of the ovarian tumor material from 
the 40 patients. Distribution of resistant (r) and sensitive (s) cases 
respectively is shown in the third column.BMC Cancer 2009, 9:368 http://www.biomedcentral.com/1471-2407/9/368
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staging and tumor grading was performed according to
the International Federation of Gynecology and Obstet-
rics (FIGO) standards. All tumors were assessed by one
pathologist, according to regional treatment guidelines
for gynecological malignancies in western Sweden. In
addition, specimen imprints for cytologic evaluation were
performed to verify the presence of tumor cells (stained
with May-Grünwald-Giemsa stain). At least 70% tumor
cells content was required for each tumor specimen. The
tumors investigated were collected from patients diag-
nosed between 1995 and 2003 at Sahlgrenska University
Hospital in Gothenburg, and the study was approved by
the local ethics committee. Median age of the patients at
initial diagnosis was 59.5 years (range 40-79 years), and
median follow-up time was 7 years (range 5-11 years)
among survivors.
Array CGH
Tiling, whole genome coverage BAC arrays (38,043 BAC
clones) were produced at the SCIBLU Genomics Center,
Department of Oncology, Lund University, Sweden http:/
/www.lth.se/sciblu as previously described [20]. BAC
clones were mapped to the hg17 genome build. Array
CGH was performed essentially as previously described
[20]. Normal female reference DNA containing a mix
from ten healthy individuals was purchased from
Promega, Madison, WI, USA. Identification of individual
spots on scanned arrays was performed with GenePix Pro
software 6.0.1.12 (Axon Instruments, Union City, CA,
USA), and the quantified data matrix was loaded into the
web-based database Bio Array Software Environment
(BASE) http://base.thep.lu.se/[21].
Data analysis
Background correction of Cy3 and Cy5 intensities was cal-
culated using median-feature and median-local back-
ground, generating test over reference log2 ratios. Flagged
features were removed and spots that had background-
corrected Cy3 or Cy5 intensities < 0 or > 65000 were
removed from further analysis. A signal-to-noise filter of 
5 for both tumor and reference channels was applied to
the data. The filtered data were normalized using the
popLowess algorithm [22]. After normalization, a smooth
was applied with a moving median sliding window of 250
kbp, and with adaptive thresholds [22]. The CGH-Plotter
software [23], as an R http://www.r-project.org imple-
mentation in BASE, was used for segmentation. The seg-
mentation constant, c, was set to 8. Copy number
alterations were determined by comparing the segmented
log2 ratios to gain/loss thresholds obtained by an adaptive
scaling method [22], using a window size of 2% and a
scaling factor of 2. Segments were accordingly designated
gained, lost or not changed, giving a ternary scale (-1, 0,
1). Using the values given by CGH-plotter the frequency
of copy number changes per tumor was calculated (alter-
ations defined as >3 adjacent clones). To facilitate any
cross-platform comparison, segmented data was trans-
formed into a virtual probe set with probes spaced at every
50 kbp throughout the entire genome by associating each
probe to its closest virtual probe [24].
Statistical analysis
Two-tailed Fisher's exact test was used to identify gains or
losses that differed significantly in frequency between the
sensitive and resistant tumor groups. A cutoff value of P <
0.01 was used to reduce the effect of multiple testing in
this large data set. Further, it has been demonstrated that
analyzing segmented data greatly increases the power to
detect true significant associations without increasing the
false discovery rate [25]. Gains were tested against no gain
and losses were tested against no loss. To test if the fre-
quency of altered genome differed between the groups,
one-tailed Student's t-test was performed. A decision tree
for classifying samples as resistant or sensitive was gener-
ated based on the significant regions using the J48 algo-
rithm in the Weka software. Tests included in the resulting
tree were based on binary decisions, i.e. gain versus no
gain and loss versus no loss. The algorithm was applied
with the default settings of Weka version 3.6.0 [26]. Clas-
sification accuracy on samples was estimated using n-fold
leave-one-out cross validation. The decision tree was fur-
ther tested on another published data set of 98 stage III
ovarian serous tumors with survival as endpoint (29 sur-
vivors versus 69 non-survivors) [27], to evaluate our find-
ings. Non-survivors were regarded as equivalent to
resistant and survivors to sensitive in the tree. Survival
curves of the significant regions were prepared using the
Kaplan-Meier method in the SPSS software, version 16
(Superior Performance Software System, SPSS for Win-
dows, Chicago, IL, USA) and P-values for the difference
between the curves were calculated using the Breslow-Wil-
coxon test [28].
Quantitative real-time polymerase chain reaction (QPCR)
QPCR was performed on 17 cases, eight resistant and nine
sensitive, to explore gene expression of the five genes
EVI1, MDS1, SH3GL2, SH3KBP1, and ABCB1. QPCR was
essentially performed as previously described [29]. In
brief, total RNA was isolated from all 40 fresh-frozen ovar-
ian tumors by homogenization with TRIzol Reagent (Inv-
itrogen, Carlsbad, CA, USA), and then extracted with
RNeasy mini kit (Qiagen, Valencia, CA, USA). After qual-
ity control of RNA using the 2100 bioanalyzer (Agilent
Biotechnologies, Palo Alto, CA, USA), 17 samples passed
and were further analyzed (RNA integrity number value:
median 6.6, range 4.7-7.9). From each tumor sample, 1 g
total RNA was reverse transcribed in duplicate, as well as
negative controls without enzyme, using the iScript kit
(Bio-Rad Laboratories, Hercules, CA, USA). Each cDNA
sample was analyzed in triplicate by real-time PCR, andBMC Cancer 2009, 9:368 http://www.biomedcentral.com/1471-2407/9/368
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detected with PerfeCTa SYBR Green Supermix (Quanta
Biosciences, Gaithersburg, MD, USA). Two reference
genes were used, GAPDH  and  -actin, both previously
found to be stably expressed in ovarian tumor material
[29]. Primer sequences for the target genes are presented
in Additional file 2:Primer sequences. Reference gene
assays used for normalization were obtained from the
Human Endogenous Control Gene Panel (TATAA Bio-
center, http://tataa.com). The efficiency of each QPCR
assay was estimated from the slope of a standard curve
generated from the serial dilution of purified PCR prod-
ucts. When analyzing the QPCR data, samples were
grouped according to the corresponding CNA exhibiting
significance in the array CGH analysis (EVI1,  MDS1,
SH3GL2,  SH3KBP1) or according to chemotherapy
response (ABCB1), and a one-tailed Student's t-test was
performed between the groups.
Results
Array CGH
Using high-resolution whole genome array CGH, we
explored copy number alterations in 40 stage III ovarian
serous carcinomas in relation to chemotherapy response.
The amount of alterations detected by array CGH varied
greatly between the samples. On average, the frequency of
altered genome was 32% per tumor, and the size of
altered genome per tumor was 946 Mbp (range 42-2137
Mbp). The majority of the samples exhibited a simplex
genome pattern, i.e. rather large low-level alterations;
however, smaller changes were also abundant. Overall,
low-level copy number alterations dominated,
homozygous deletions were scarce, and high-level ampli-
fications were not very frequent. The most frequent CNAs
in the total material were gains in 1q, 3q, 8q, 20pq, and
losses in 4q, 8p, 17p and Xpq. The original array CGH
data are available in Additional file 3:Array data.
For the two response groups, the average frequency of
altered genome was 38% in resistant cases, whereas 26%
in sensitive cases (Figure 1). The difference was statisti-
cally significant (P = 0.044). Exploring the genetic altera-
tion pattern in the ovarian tumors in relation to
chemotherapy response revealed regions in four chromo-
somal arms that differed significantly between the sensi-
tive and resistant cases, and that were more frequent in the
resistant tumors (Table 2). Gain in region 3q26.2 was sig-
Genome-wide frequency plot Figure 1
Genome-wide frequency plot. Genome-wide frequency plot of the CNAs in the total ovarian tumor material consisting of 
40 tumors. Genomic fragments are in chromosomal order as indicated; gains are upwards and losses downwards. Black line 
represents resistant cases, and red line sensitive cases.BMC Cancer 2009, 9:368 http://www.biomedcentral.com/1471-2407/9/368
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nificantly more frequently detected in the resistant cases.
It is a small region (150 kbp) containing only two known
genes (EVI1  and  MDS1). The region was the smallest
region of overlap (SRO) in 3q26 and 65% of the resistant
cases displayed gain in the region; whereas 20% of the
sensitive cases. Some tumors exhibited gain peaks exclu-
sively in the SRO (Figure 2B) and some exhibited peaks in
the close proximity of the significant region. Further,
losses in three regions in chromosome arm Xp (Xp22.2-
22.12, Xp22.11-11.3, Xp11.23-11.1) were significantly
more frequent in resistant cases than sensitive cases (Table
2). The regions are rather large and most tumors displayed
alterations extending along a major part of the p-arm, and
along the q-arm as well (Figure 2C). The alteration pattern
was simplex and none displayed homozygous deletions.
The significant regions together contain 265 known genes
with varying types of functions. Additionally, losses in
three regions in chromosome arm 9p (9p22.3, 9p22.2-
22.1, 9p22.1-21.3) were significantly associated with
resistance (Table 2). The three closely situated regions are
quite small and contain 11 known genes. Alterations in
the regions were rather large and many extended along
half the p-arm (Figure 2D). A further significant region
associated with resistance was 6q11.2-12 (Table 2). It is a
4.85 Mbp large region harboring 16 known genes, of
which none seems to be of obvious interest.
A decision tree was generated based on the significant
regions, and regions 6q11.2-12, Xp11.3 and Xp22.13
were picked out as the best combination of classifiers (Fig-
ure 3). It classified all sensitive cases and 16/20 resistant
cases correct with a total correct classification of 90%, and
Frequency plots Figure 2
Frequency plots. A) Frequency plot of chromosome arm 3q. The significant region in 3q26.2 is highlighted in grey. B) Exam-
ple of one case exhibiting a SRO gain peak in the significant region 3q26.2 only. BAC clone segments are matched to their size. 
All genes in the region are displayed and those in the significant region are highlighted in yellow. C) Frequency plot of chromo-
some X. The significant regions are highlighted in grey, and the gene SH3KBP1 that was explored with QPCR is shown. D) Fre-
quency plot of chromosome 9. The significant regions are highlighted in grey, and the gene SH3GL2 that was explored with 
QPCR is shown. In all frequency plots: resistant cases (black line) versus sensitive cases (red line).BMC Cancer 2009, 9:368 http://www.biomedcentral.com/1471-2407/9/368
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in the leave-one-out cross-validation it showed an accu-
racy of 78%. When testing the decision tree on a pub-
lished data set from Partheen and colleagues [27],
samples with alterations in the decision tree regions were
classified correctly at a high frequency (88% non-survi-
vors correctly for the first node 6q11.2-12, and 82% for
the third node Xp22.13) whereas samples without any of
the alterations were poorer classified (37% correctly clas-
sified). To illustrate the value of the significant regions for
patient survival, Kaplan-Meier curves are shown in figure
4.
The much studied and commonly altered region 7q21.12,
harboring the multidrug resistance gene ABCB1, was scru-
tinized in the present material though it did not exhibit
significance. Alterations in the region were scarce, and
those present did not vary between sensitive and resistant
cases; no amplifications or homozygous deletions were
found in the region
QPCR
In the significant genomic regions established by array
CGH we located four genes of specific interest for ovarian
cancer and chemotherapy response; EVI1,  MDS1,
SH3KBP1  and  SH3GL2. The genes MDS1  and  EVI1  at
3q26.2 have been shown by others to be of great interest
for ovarian cancer, and have also been implicated in pacl-
itaxel resistance [30-33]. The gene SH3KBP1/CIN85,
located at Xp22.1-21.3, is an essential part of the complex
Table 2: Significant regions
cytoBand 
(+ gain, - loss)
Mbp startPos 
(BAC)
Mbp endPos 
(BAC)
Size (Mbp) cases resistant 
(%)
cases sensitive 
(%)
P-value No. of genes
+ 3q26.2 170150001 
(RP11-152C17)
170300002 
(RP11-252J1)
0.15 65 20 0.0095 2
- 6q11.2-12 63400001 
(RP11-692G18)
68250002 
(RP11-164N24)
4.85 40 0 0.0033 16
- 9p22.3 15100001 
(RP11-271D19)
16150002 
(RP11-141K7)
1.05 45 5 0.0084 6
- 9p22.2-22.1 17750001 
(RP11-601F21)
18550002 
(RP11-269F13)
0.8 45 5 0.0084 2
- 9p22.1-21.3 19650001 
(RP11-61D22)
20800002 
(RP11-66P3)
1.15 45 5 0.0084 3
- Xp22.2-22.12 15250001 
(RP11-438H12)
20750002 
(RP11-451E9)
5.5 60-65 15 0.0031-0.0079 39
- Xp22.11-11.3 24050001 
(RP11-79B3)
46900002 
(RP11-571E6)
22.85 60-70 15-20 0.00077-0.0095 141
- Xp11.23-11.1 49250001 
(RP11-122N23)
58250002 
(RP11-96A5)
9 60-65 10-15 0.00077-0.0079 85
Regions exhibiting statistical significance (P < 0.01) between sensitive and resistant cases. The intervals in frequency numbers and P-values are due 
to CNA gaps inside the significant regions.
Decision tree Figure 3
Decision tree. A decision tree based on the significant 
regions chose 6q11.2-12, Xp11.3 and Xp22.13 as the best 
combination of classifiers. Numbers beneath the circles are 
the number of cases classified in each group. Numbers in 
brackets are incorrectly classified cases if any. R = resistant, S 
= sensitive.BMC Cancer 2009, 9:368 http://www.biomedcentral.com/1471-2407/9/368
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controlling endocytosis of the epidermal growth factor
receptor (EGFR) [34], which has been implicated in pacl-
itaxel and cisplatin response [35,36]. Additionally, the
protein of the gene SH3GL2/Endophilin A1, located in
9p22.2-22.1, binds to SH3KBP1 in the complex that con-
trol endocytosis of EGFR [34]. Therefore, these genes were
selected for gene expression analysis.
Samples were separated according to the corresponding
CNA pattern for each gene, and we aimed to explore and
compare the relative gene expression between these
groups. Unfortunately, high quality RNA was achievable
from only 17 of the 40 tumor samples, thus weakening
the results obtainable. The relationships between gene
expression and CNA are illustrated in figure 5. Concerning
EVI1, the average relative expression differed between the
samples with gain and without gain, with higher expres-
sion in the gain group (1.8 times higher). The difference
was borderline significant (P = 0.068). Figure 6 illustrates
the correlation between DNA and mRNA for the EVI1
gene. Expression of the MDS1 gene was detected in all
samples; however there was no significant difference
between samples with gain and without gain (Figure 5B).
Nor did we find a significant correlation to the array CGH
findings for the SH3KBP1 gene (Figure 5C). Further, the
gene expression of SH3GL2 was generally very low, unde-
tectable even in some samples. Therefore, accurate and
reliable calculations were impaired. A slight tendency was
noticed however; the group with DNA losses exhibited
lower relative mRNA expression than the group without
losses. Moreover, the expression levels of the four genes
Survival curves Figure 4
Survival curves. Survival curves for the significant regions in 3q26.2, 6q11.2-12, 9p22.3-21.3, and Xp22.2-11.1. The lines rep-
resent the survival of patients whose tumors exhibit or do not exhibit the significant alterations in the respective regions.BMC Cancer 2009, 9:368 http://www.biomedcentral.com/1471-2407/9/368
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investigated did not differ significantly when grouped
according to resistance.
In addition, we explored gene expression of the much
studied multidrug resistance gene ABCB1 (also known as
P-glycoprotein/P-gp or multidrug resistance 1/MDR1),
and compared the relative expression between sensitive
and resistant groups (Figure 5D). The overall expression
of ABCB1 was quite low, and there was no significant dif-
ference between sensitive and resistant cases. If scrutiniz-
ing the data, one might see a tendency that the resistant
group exhibit lower expression on average than the sensi-
tive group.
When studying the pattern of CNA co-occurrence for the
SH3KBP1 and SH3GL2 loci, losses in any of the two loci
occured in 14/20 (70%) of the resistant cases, with 8 cases
of co-losses, and 6 cases with loss in only one of the two
loci. The sensitive cases exhibited only 1 co-loss and 2
cases with one of the two loci lost.
Discussion
The majority of ovarian cancer patients is diagnosed with
advanced stage disease of serous histology and treated
with combination chemotherapy paclitaxel/carboplatin.
In the present investigation we selected only stage III
Expression data Figure 5
Expression data. Relative mRNA expression for genes ana-
lyzed with QPCR. Each plot shows the median (centre lines), 
interquartile ranges (boxes), largest and smallest values 
(whiskers) that are not outliers (circles), or extreme values 
(stars) within a category. Samples for the genes EVI1 (A), 
MDS1 (B), and SH3KBP1 (C) are grouped according to the 
corresponding CNA exhibiting significance with array CGH. 
Samples for the gene ABCB1 (D) are grouped according to 
chemotherapy response.
DNA-RNA correlation for EVI1 Figure 6
DNA-RNA correlation for EVI1. A heatmap illustrating 
the mRNA and DNA correlation for the EVI1 gene and its 
locus 3q26.2. Red represents gain and high mRNA expres-
sion, respectively, whereas green represents no gain and low 
expression. Black represents intermediate levels of mRNA 
expression. In the left panel, tumors were clustered hierar-
chically according to similarity, using both copy number and 
expression level in the distance calculation (Euclidean). The 
chemotherapy response status of the samples is indicated 
vertically for each sample respectively. R = resistant case, S = 
sensitive case.BMC Cancer 2009, 9:368 http://www.biomedcentral.com/1471-2407/9/368
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serous primary specimens from patients homogenously
treated with adjuvant paclitaxel/carboplatin in order to
refine the analysis. Using array CGH, we detected specific
genetic alterations associated with resistance, of which
some might be potential predictive markers of chemother-
apy resistance in advanced ovarian cancer.
Several non-overlapping single genes, gene profiles and
CNAs have been suggested as potential markers for chem-
otherapy response in ovarian cancer [12,13,37-39]. To our
knowledge, there are only a few reports on chemotherapy
resistance in ovarian cancer using array CGH [12-15].
There are also prior studies using conventional metaphase
CGH to investigate platinum resistance in ovarian cancer
[16-19]. Unfortunately, results are diverse. The disagree-
ment, however, can partly be explained by the use of var-
ious CGH platforms, variations in resistance
classifications, heterogeneous tumor materials, and the
use of various cell lines. It also emphasizes the difficulty
of investigating chemotherapy resistance in ovarian can-
cer. Hence, additional studies are needed in order to clar-
ify the complex pattern of genetic alterations associated
with chemotherapy response in ovarian carcinomas and
to identify reliable predictive markers.
In the current study, we associated CNAs in four chromo-
somal arms with chemotherapy resistance in stage III
ovarian serous carcinomas. Gain in the small region at
3q26.2 was significantly established as frequently more
present in resistant cases (65%) than sensitive cases
(20%). 3q26 is recurrently found amplified in various
cancer types including ovarian carcinoma [40-42]. In con-
cordance with our results, Nanjundan and colleagues
identified the ~2 Mbp wide region at 3q26.2 containing
EVI1 and MDS1 to be the most frequent region of copy
number gain in an ovarian tumor material [30]. Addition-
ally, Kim and colleagues found gain in 3q26.2 in more
than 70% of serous ovarian cancer specimens; equally
abundant in sensitive and resistant cases [13]. The two
genes in the significant region are of great interest. EVI1 is
an oncogene frequently associated with leukemogenesis
[43], and also with other cancer types such as lung- and
endometrial cancer [44,45]. It has been found over
expressed in ovarian cancer and implicated in ovarian car-
cinogenesis [30-32]. Interestingly, Liu and colleagues
showed that the protein Evi1 inhibited paclitaxel-medi-
ated apoptosis, thus causing resistance [33]. In this con-
text, our finding of gain in 3q26.2 as overrepresented
among resistant cases is highly interesting. Further, Sunde
and colleagues found a significant correlation between
gene copy number and EVI1 gene expression, and sug-
gested that enhanced expression of EVI1  can partly be
explained by increased gene copy number [31]. We did
not detect such a strong correlation, but a tendency was
noticed in that direction, and enlarged studies scrutiniz-
ing EVI1 gene and protein expression may elucidate its
role in ovarian cancer and chemotherapy response. Addi-
tionally, among the tumors exhibiting gains in 3q26,
some display a gain peak specifically in the significant
region 3q26.2, whereas others display gains extending
over a larger region, and a few exhibit peaks in the sur-
rounding regions. This complex pattern of CNAs suggests
that more than one driver might exist for the 3q26 gain, as
correspondingly detected and stated by others [30]. MDS1
was first identified as a component of the AML1-MDS1-
EVI1 fusion transcript in myeloid leukemia [46], and very
little is known about the gene product when not in a
fusion transcript. MDS1 was expressed in the current ovar-
ian tumor material, but the expression results did not cor-
relate with the findings on the DNA level, nor resistance.
Losses in three regions in chromosome arm Xp (Xp22.2-
22.12, Xp22.11-11.3, Xp11.23-11.1) were associated with
chemotherapy resistance in the current study. The altera-
tions detected here were large, stretching along the whole
chromosome in some cases. The X chromosome has not
been explored to the same extent as the rest of the genome
by CGH due to the use of male reference in several studies.
Losses in the X chromosome has been found in cisplatin-
resistant cell lines [14-17]. When scrutinizing the 265
known genes in the significant regions found in Xp, our
attention was drawn to SH3KBP1, also known as CIN85.
Loss of the SH3KBP1 locus as found in our investigation
could be a form of resistance mechanism by inhibiting
EGFR endocytosis and thus increasing EGFR signaling,
which might reduce sensitivity to paclitaxel and/or plati-
num drugs [35,36]. When exploring mRNA expression
levels of SH3KBP1 we did not find a difference between
samples with loss and no loss, nor resistance. However,
we were only able to investigate a small subset of the
tumor material, and further studies of the gene should be
encouraged on both mRNA and protein expression levels.
Additionally, three small regions of loss in chromosome
arm 9p (9p22.3, 9p22.2-22.1, 9p22.1-21.3) were associ-
ated with resistance. In ovarian cancer, allelic imbalances
are commonly detected in 9p [41], but the region have to
our knowledge not been associated with chemotherapy
resistance earlier. The gene SH3GL2 located in 9p22.2-
22.1, also known as Endophilin A1, is as SH3KBP1 also
part of the complex controlling endocytosis of EGFR [34].
Thus, equally interesting in association to chemotherapy
resistance as SH3KBP1. Unfortunately, the gene showed
generally low expression in the ovarian tumor samples
and reliable calculations were unfeasible. Still, continued
exploration of the gene and its locus should be of interest
due to its strong associations to EGFR and chemotherapy
response.BMC Cancer 2009, 9:368 http://www.biomedcentral.com/1471-2407/9/368
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We find it very interesting that the proteins of the genes
SH3KBP1 and SH3GL2, located in two different regions
exhibiting significance in the current study, both have
been shown to physically bind and interact in the com-
plex controlling endocytosis of EGFR [34]. Losses in any
of the two loci were found in 70% of the resistant tumors.
Overall, mRNA expression indicated only weak DNA copy
number dependence in our study. However, we were only
able to obtain high quality RNA from a subset of the
tumor material (17/40) which obviously might influence
the results. Additionally, further exploration of genes in
the significant regions would be of interest. Reliable
genetic alteration profiles, however, can be of great inter-
est as predictive markers of patient outcome regardless of
its influence on gene expression; and DNA is relatively
easy to handle and more stable than RNA.
The decision tree that was generated based on the signifi-
cant regions, specifically discerned the regions 6q11.2-12,
Xp11.3 and Xp22.13 as a good combination of classifiers
and predictors of chemoresistant or chemosensitive dis-
ease in our tumor material (Figure 3). Losses in the signif-
icant region 6q11.2-12 were found exclusively in the
resistant tumors, and as shown by the decision tree loss in
6q11.2-12 classified 8 resistant tumors at once. Addi-
tional losses in Xp11.3 and Xp22.13 further classify 8
resistant cases. Conversely, lack of these changes classified
all sensitive cases correct. This indicates a specific impor-
tance of these genomic alterations, and region 6q11.2-12
is therefore of great interest as a predictive marker of
chemoresistant disease. As mentioned above, the altera-
tions detected in Xp were not restricted to the significant
regions in the majority of cases. Thus, losses in general in
Xp ought to be considered interesting for chemotherapy
resistance. We further tested the decision tree on another
published ovarian tumor material with corresponding
stage and histology but with a different combination
treatment (carboplatin, farmorubicine and cyclophospha-
mide) and survival as end point [27]. When scrutinizing
the tree, samples exhibiting alterations in the decision tree
regions were correctly classified at a rather high frequency
(88% and 82%, respectively), whereas samples lacking
alterations in the regions were poorly classified (37%).
This is in concordance to our material, where the only
misclassifications were samples without alterations in the
regions. It suggests that alterations in these regions are of
importance for the outcome in advanced stage ovarian
serous tumors. Tumors without alterations in these
regions, on the other hand, need further characterization.
Additionally, all resistant cases in our study died of their
disease and all sensitive cases exhibited more than five-
year survival; and the importance of the significant
regions in relation to patient survival is shown by the sur-
vival curves in figure 4. Since the decision tree contains
regions in chromosome X, and many studies do not ana-
lyze X as mentioned above, testing of the tree in further
published materials is unfortunately hampered.
We detected a significantly higher frequency of genomic
alterations in resistant specimens than in sensitive speci-
mens, which has been reported in similar studies [12-14].
This elevated frequency of genetic alterations might
present an advantage for the resistant tumors, and help
them to adapt in the hostile chemotherapy environment.
The phenomenon of multidrug resistance (MDR) has
been shown to effect paclitaxel [5]. However, the rele-
vance of MDR in ovarian cancer treatment is not clear
[47]. A number of reports have focused on multidrug
resistance in ovarian carcinoma, and specifically on the
drug efflux pump P-glycoprotein, whose gene ABCB1 is
situated in 7q21.12 [48-50]. The gene has been found
over expressed in paclitaxel-resistant ovarian and lung
cancer cell lines [48,49]. In the current study, we took the
opportunity to study ABCB1  in our primary ovarian
tumor material. ABCB1 showed generally low expression
and CNAs in 7q21.12 were infrequent; no differences
were seen between sensitive and resistant cases, which is
in concurrence with others [51].
Conclusion
In conclusion, we identified gains in 3q26.2, and losses in
6q11.2-12, 9p22.3-21.3, and Xp22.2-11.1 to be associ-
ated with chemotherapy resistance, suggesting that these
CNAs might have a potential as predictive markers of
chemoresistant disease in patients with advanced ovarian
serous cancer. Identifying a high-risk group of patients
that will exhibit poor response to conventional chemo-
therapy could lead to a different treatment regiment
already at first-line therapy and a special follow-up of
these patients. However, this is a pilot study with a small
material and further studies are needed to evaluate and
verify the results. Still, our findings contribute to an
increased understanding of the genetic alterations in
chemoresistant ovarian serous carcinoma.
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